HR NEWS

Carfilzomib may up risk of cardiovascular problems: Study

Carfilzomib may up risk of cardiovascular problems: Study

Taking a higher dose of carfilzomib, an anti-cancer drug, may increase the risk of cardiovascular problems, a study warns. An analysis of past studies showed 18 per cent of multiple myeloma patients receiving carfilzomib experienced cardiovascular adverse events (CVAE) such as hypertension, heart failure, heart attacks, or arrhythmia. More than eight per cent of patients experienced high- grade CVAEs that are more severe, which is more than twice as common as with other drugs for treating relapsed myeloma. Carfilzomib is one of three proteasome inhibitors currently approved for use by the US Food and Drug Administration (FDA), said researchers from the University of Pennsylvania in the US. Proteasomes are essentially garbage workers that break down and eliminate proteins inside a cell. Diseases that require more protein turnover to survive, like Multiple myeloma (MM), need more proteasomes. The inhibitor drugs block them from doing their job, causing the cells to fill up with protein and die.

“Like any cancer therapy, the concern with this approach is that it may have an effect on an otherwise healthy part of the body – in this case, the heart,” said Adam J Waxman, from the University of Pennsylvania. For the study published in the journal JAMA Oncology, the researchers gathered data from 24 studies reported from 2007 through 2017, which included information on 2,594 MM patients. They found 18.1 per cent of patients who took carfilzomib experienced CVAE, with 8.2 per cent of those cases being grade three or higher, meaning they are categorised as severe.

For comparison, a similar review of bortezomib, another proteasome inhibitor, found just 3.8 per cent of patients experienced CVAE and only 2.3 per cent were severe. The most common CVAEs were hypertension (12.2 per cent) and heart failure (4.1 per cent). Arrhythmias (2.4 per cent) and ischemic events (1.8) – in which there isn’t enough blood flow to the heart leading to the death of heart muscle – were observed less commonly. They also found that higher doses of carfilzomib are associated with higher rates of CVAE, and that carfilzomib was associated with an elevated risk of CVAE compared to control groups who did not receive carfilzomib.

Source: Financial Express

5 months ago

By HR Reporters

Related Tags :   • Health News

Social Share : Share      

Comments.....

Submit new comment

Most Viewed

Air India unauthorised payment scam: Chief Vigilance Officer Shobha Ohatker unde...

10 months ago

Uber hires legal chief Tony West from Pepsi amid mounting pressure...

8 months ago

Prosecutors appeal against ruling on Samsung heir...

10 months ago

Railways can create 1 million jobs; global tender soon for tracks...

8 months ago

Snapdeal CFO Anup Vikal quits; acquisition talks with Flipkart collapse...

8 months ago

Carfilzomib may up risk of cardiovascular problems: Study...

5 months ago

This company spent $6m to close gender pay gap...

8 months ago

Arundhati Bhattacharya – Captain Courageous: SBI chairman weathered NPA storm an...

8 months ago

FE Best Bank Awards - 2017 Declared...

6 months ago

Ketamine may reduce suicidal thoughts, says study...

6 months ago

Most Shared

Mass redundancies for Quebec cookie factory...

2 years ago

Trump this: 5 bold predictions for how he’ll impact HR...

2 years ago

InfoTycoon appoints existing President and COO Kevin George to succeed James Dav...

2 years ago

Sushant Dwivedy joins Aspiring Minds as SVP-Enterprise Client Solutions...

2 years ago

Uber introduces special reward programme...

2 years ago

Standard Chartered Bank to reduce 10% corporate & institutional banking staff...

2 years ago

National CineMedia (NCM) creates Affiliate Partnerships team, names Stacie Tursi...

2 years ago

OCC Names New CFO, Treasurer, and Chief Compliance Officer...

2 years ago

Beards at work are now a major turn-off say 61% of female office workers...

2 years ago

First female fast jet pilot of Britain hired as director at PwC...

2 years ago